Get the Stockscreener App
6.54
6.00%
0.37
Pre-market:
6.57
0.03
+0.46%
Unicycive Therapeutics Inc stock is traded at $6.54, with a volume of 279.48K.
It is up +6.00% in the last 24 hours and up +47.30% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$6.17
Open:
$6.23
24h Volume:
279.48K
Relative Volume:
0.62
Market Cap:
$140.55M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-4.2194
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
+3.81%
1M Performance:
+47.30%
6M Performance:
+743.87%
1Y Performance:
+821.13%
1-Day Range:
$6.1405
$6.55
1-Week Range:
$5.77
$6.70
52-Week Range:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.54 | 132.60M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Important Notice to Long-Term Shareholders of Five Below, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics to Participate in Upcoming Investor Events in December - Black Hills Pioneer
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Unicycive Therapeutics Inc. stock a top momentum playJuly 2025 Reactions & Daily Profit Maximizing Tips - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (Nasdaq: UNCY) to join Piper Sandler and Noble investor events - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
Can Unicycive Therapeutics Inc. stock double in next 5 yearsJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com
Sentiment analysis tools applied to Unicycive Therapeutics Inc.Options Play & Long-Term Capital Growth Ideas - newser.com
Will Unicycive Therapeutics Inc. stock maintain growth storyQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Can Unicycive Therapeutics Inc. stock attract ESG capital inflowsWatch List & Daily Chart Pattern Signals - newser.com
What moving averages say about Unicycive Therapeutics Inc.Weekly Trade Analysis & Consistent Growth Stock Picks - newser.com
What catalysts could drive Unicycive Therapeutics Inc. stock higherEarnings Overview Report & Precise Buy Zone Tips - newser.com
How rising interest rates impact Unicycive Therapeutics Inc. stockWeekly Trade Review & Daily Oversold Stock Bounce Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well - Yahoo Finance
Unicycive Therapeutics, Inc.Common Stock (NQ: UNCY - Markets Financial Content
How Unicycive Therapeutics Inc. stock compares to growth peersJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Can Unicycive Therapeutics Inc. stock hit analyst price targets2025 Performance Recap & AI Powered Buy/Sell Recommendations - newser.com
Live market analysis of Unicycive Therapeutics Inc.July 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):